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was not a statistically signiﬁcant predictor for MACE (OR 1.65, 95% CI
0.78-3.50, p¼0.2) after adjustment for confounders.
CONCLUSIONS This study, the ﬁrst to examine an FFR guided strategy in
DMpatients, shows similar MACE rates in both groups, however the event
rateswere numerically higher in the DG. The differencewasmainly driven
by a signiﬁcantly higher rate of TLR and re-hospitalization for ACS, and a
numericallyhigher rateofMI.Due to its limitedpower, this studyshouldbe
considered as hypothesis generating, however it raises the question if an
FFR-guided revascularization strategy is safe in patients with fast pro-
gressing plaque as in DM patients.
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BACKGROUND The management of coronary in-stent restenosis (ISR)
is challenging and the most effective interventional treatment is still
undeﬁned. We aimed to compare different interventional strategies
for coronary ISR to assess the relative efﬁcacy in reducing target lesion
revascularization (TLR).
METHODS Randomized trials comparing two different treatmentswere
searched in PubMed, Embase, Scopus, Cochrane Library, Web of Science,
and ScienceDirect electronic databases and major scientiﬁc websites. The
searchwasperformed fromthedateofdatabases inception to 30December
2014. Patients of any age, gender, ischemic risk proﬁle, and clinical pre-
sentation were included and any type of ISR, both bare-metal stent(BMS)-
ISR and drug-eluting stent (DES)-ISR, both ﬁrst ISR and recurrent ISR, was
considered. Trials comparing non-interventional treatments, variants of
the same typeof device,multiple strategies for ISR in the samegroupat the
same timewere excluded. The endpointwas TLR, deﬁned as any repeated
revascularization involving the target lesion, both percutaneous and sur-
gical, at 6-12 months. Data used in this meta-analysis were intention-to-
treat. A hierarchical Bayesian networkmeta-analysiswas carried out using
a random effects consistency model computed by Markov Chain Monte
Carlo methods with Gibbs sampling based on 100,000 iterations following
discard of 50,000 “burn-in” iterations. Posterior inference was expressed
as odds ratio (OR) and 95% credibility interval (CrI). Heterogeneity was
graded using I2 statistic. Inconsistency was explored using network
“node-split”.
RESULTS A total of 24 trials (4,880 patients) and 7 interventional
treatments (Plain Balloon [PB], drug-coated balloon [DCB], DES, BMS,
brachytherapy [BT], rotational atherectomy [ROTA], and cutting
balloon [CUT]) were included in this meta-analysis. DCB and DES were
associated with a signiﬁcant reduction in the risk of TLR compared
with all the other treatments. PB anti-restenotic effect was comparable
with those of BMS, BT, ROTA, and CUT. No difference in TLR between
DCB and DES was observed (DCB vs. DES: OR 1.11, 95% CrI 0.59-2.07).
CONCLUSIONS DCB and DES are the most effective interventional
strategies for ISR and PB alone should no longer be considered. BMS,
BT, ROTA and CUT present anti-restenotic effects similar to PB.
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BACKGROUND Patients presenting with recurrent angina after a
remote history of coronary artery bypass grafting (CABG) represent a
challenge in adequately resolving symptoms due to native disease
progression, and graft attrition. While the favored treatment modal-
ities consist mainly of medical therapy or percutaneous coronary
intervention (PCI), there is limited data available on the subsequent
clinical outcomes. We therefore report the long term outcomes of
patients with a history of CABG who underwent repeat angiography
for recurrence of stable angina.
METHODS We retrospectively collected clinical data on patients with a
history of prior CABG who underwent angiography after presenting with
angina between Jan 2008 and Dec 2012. Treatment allocation was at the
physician’s discretion at the time of angiography. Data was collected from
the hospital angiography database, outpatient review and welsh de-
mographic service. Patients presenting with an ACS were excluded.
RESULTS 287 consecutive patients (mean age 67.6 yrs, 88% male) un-
derwent coronary angiography after presenting with angina. 173 patients
were treatedmedically, 114 patients treated with PCI. Patients assigned to
medical therapy had lower mean CCS angina class compared to the PCI
cohort (2.16 vs 2.50 p<0.001). Both groups were well matched for baseline
demographics. In the PCI group, native vessels were treated in 78.9% of
cases and vein grafts in 21%. Following treatment, angina status decreased
signiﬁcantly in both groups (0.96 formedically treated and 1.33 for the PCI
group, p<0.001 for both, P¼ns between groups). Mean NYHA class also
decreased signiﬁcantly in both groups (by 1.06 for the medically treated
group and 1.1 for the PCI group p<0.001 for both groups P ¼ns between
groups). In the PCI group signiﬁcant improvement in anginawas greater in
the native vessel group compared to the graft PCI groups (1.27vs1.07
p<0.05). Therewas higherMACE rates at 1 year in themedical group 21.4%
vs 7.0% in the PCI group (p<0.001). This was driven mainly by MI and
rehospitalization for cardiac causes (18.5% and 25.4% respectively in the
medical group compared to 5.3%, 12.3% for the PCI group). Over a mean
followupperiodof 3 years, therewasnodifference in all-causemortality in
either cohort (Medical 7.5%vsPCI 4.3% p¼0.18). One year mortality was
higher in vein graft PCI group than native vessels (0% vs 8%, P<0.05).
CONCLUSIONS In patients presenting with recurrent angina after previ-
ous CABG, patients treated with PCI had higher angina burden than those
treated medically. Equivalent symptomatic improvements was achieved
with PCI andmedical therapy. Therewas signiﬁcantly lessMACE in the PCI
group compared to medical therapy with a trend to mortality beneﬁt at
3yrs. Native vessel PCI had better 1yr outcomes than SVG-PCI in these
subgroups. Once patients represent with angina post CABG, continuing
symptom burden and recurrent clinical events remains problematic and
further treatments are required to optimize outcomes.
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BACKGROUND Drug-eluting stent (DES) and drug-coated balloon
(DCB) seem to be the most effective treatments for coronary in-stent
restenosis (ISR). We performed a meta-analysis of randomized trials
comparing DES and DCB for ISR in the attempt to deﬁne whether one
of these treatments presents a higher anti-restenotic efﬁcacy.
METHODS Randomized trials comparing DES and DCB for ISR were
searched inPubMed,Embase,Scopus,CochraneLibrary,WebofScience,and
ScienceDirect electronic databases. No clinical or angiographic restrictions
were imposed. The endpoint was target lesion revascularization (TLR) at 12
months, deﬁned as any repeated revascularization involving the target
lesion, both percutaneous and surgical. Data used in thismeta-analysis were
J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y , V O L . 6 6 , N O . 1 5 , S U P P L B , 2 0 1 5 B203intention-to-treat.Astandardpair-wisemeta-analysiswascarriedoutusinga
DerSimonian-Lairdrandomeffectsmodel.Riskdistributionwasexpressedas
odds ratio (OR) and 95% conﬁdence interval (CI). Heterogeneity was graded
using I2 statistic. Trial sequential analysis is similar to interim analyses in a
single trial, where monitoring boundaries are used to decide whether a trial
could be terminated early when a p value is sufﬁciently small. Monitoring
boundaries were generated using the O’Brien-Fleming a-spending and the
required diversity adjusted information size was estimated.
RESULTS Six randomized trials (1,161 patients) were included in this
meta-analysis. Pooled estimate tended to favor DES but the difference
was not signiﬁcant (OR 0.66, 95% CI 0.33-1.31, p ¼ 0.235). Heteroge-
neity was moderate (I2 ¼ 56%). At trial sequential analysis, the cu-
mulative z-curve did not cross the traditional boundary (1.96
cumulative Z-Score) and the trial sequential monitoring boundary (a-
spending adjusted 95% CI 0.26-1.66), but neither futility boundary
was overlapped indicating that, adding patients to the comparison,
DES could produce a 50% relative risk reduction in 12-month TLR. The
anticipated number of patients required was 1,871.
CONCLUSIONS DES may have superior anti-restenotic efﬁcacy
compared with DCB, but the difference is not signiﬁcant. Trial
sequential analysis advices that an adjusted number of 1,871 patients
is required to show a signiﬁcant TLR risk reduction with DES and,
since futility boundary are not crossed, conﬁrms that adding patients
to this comparison the difference can became signiﬁcant.
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BACKGROUND Signiﬁcant unprotected left main coronary artery ste-
nosis (ULMCA) is an accepted indication for coronary artery bypass
grafting (CABG). However CABG is no option in a number of clinical
conditions. Percutaneous coronary intervention (PCI) can be performedeven under these unfavorable conditions. We sought to describe the
procedural characteristics and 5-year outcomes of the non-selected
population undergoing ULMCA PCI at our tertiary care Institution.
METHODS All consecutive patients undergoing UL PCI at the Hun-
garian Institute of Cardiology between Jan. 1, 2007 and Dec. 31, 2008
are included in this study. The choice of devices including stents (bare
metal or drug eluting (DES) stents), stenting strategy (single or two-
stent technique) and the use of intraaortic balloon pumps were left to
the discretion of the operator. 5-year follow-up data concerning sur-
vival, myocardial infarction (MI), repeat revascularization and
recoronary angiography were collected using the institutional data-
base, contacting the patients, their families, other hospitals and the
National Health Insurance database.
RESULTS 76 patients underwent ULMCAPCI at our Institution during the
study period. Their baseline clinical characteristics are shown in Table 1.
The indication for ULMCA PCI was angina pectoris in 18 (24%), non-ST-
segment elevation acute coronary syndrome (ACS) in 32 (42%), ST-eleva-
tionmyocardial infarction in 11 (14,5%), cardiogenic shock caused byMI in
13 (17%) and heart failure not related to ACS in 2 cases (2,5%). 61 patients
(80%) received a DES in ULMCA. No patient suffered a peri-procedural MI
or stroke. 30-day mortality was 14,5%, 5-year mortality 50%. In ROC
analysis, EuroSCORE II was the best predictor of 5-year survival (AUC
0,727). Survival according to different SYNTAX score tertiles was not
signiﬁcantly different. 2 suffered a fatal MI, 3 patients had a non-fatal MI
during follow-up. 3 patients had signiﬁcant in-stent restenosis (ISR) in
ULMCAall successfully treated by rePCI. Another 11 patients had rePCI and
3 CABG because of non-ULMCA ISR. Inmultivariate analysis,male gender,
age, GFR, presence of diabetes mellitus and SYNTAX score emerged as
independent predictors of 5-year event free survival. There was no acute
stent thrombosis, we had one probable subacute stent thrombosis, one
deﬁnite late stent thrombosis in the LAD (but not in the ULMCA) and one
possible very late stent thrombosis.Age, years  SD [IQR] 70,1  11,4 [61,8-78,2]
Male (%) 42 (55)Hypertension (%) 62 (82)Diabetes mellitus (%) 25 (33)Dyslipidemia (%) 54 (71)Previous myocardial infarction (%) 23 (30)Previous PCI (%) 12 (16)Previous CABG (%) 7 (9)LVEF on echo, %  SD [IQR] 45  14 [35-55]
EuroSCORE II  SD [IQR] 14,81  17,27 [2,8-26,2]
Additive EuroSCORE  SD [IQR] 10,2  4,6 [7-15]
Logistic EuroSCORE  SD [IQR] 25,25  23,80 [6,1-47,9]
ACEF score  SD [IQR] 1,82  0,82 [1,2-2,3]
GFR, ml/min/1,73m2 SD [IQR] 61,9  29,5 [41,9-82,8]
SYNTAX score  SD [IQR] 27,3  12,2 [17-37,5]CONCLUSIONS ULMCA PCI can be applied with good long-term re-
sults in patients who cannot undergo CABG because of the clinical
scenario, comorbidities or advanced age. The clinical presentation and
downstream disease have a major inﬂuence on the 5-year outcome of
the patients.
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BACKGROUND Stent fracture (SF) is a rarely reported complication of
percutaneous coronary interventions (PCI). It is more commonly re-
ported with older generation stents particularly the sirolimus eluting
stent. We sought to deﬁne our experience and outcome of subjects
presenting to our center with SF.
METHODS We identiﬁed all mention of the term ’stent fracture’ from all
reports in the cardiac catheterization laboratory database over a 10 year
period, from 2006 to 2015 (ﬁrst quarter). All coronary SF were identiﬁed.
Subjects who refused authorization for use of their medical record in
researchwereexcluded.Themedical recordandcoronaryangiogramsof the
remainderwere reviewed. This studywas approvedby theMayoClinic IRB.
RESULTS 16 patients with 18 SF events were identiﬁed at median age of
62.0 (IQR 48.1-71.2) years, 0.6 (IQR 0.3-1.7) years after stent implantation;
